WithdrawnPhase 3NCT06120673
REmission in Membranous Nephropathy International Trial (REMIT)
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Queensland
- Principal Investigator
- Chen Au PehThe University of Adelaide
- Intervention
- Obinutuzumab(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (13)
- Canberra Hospital, Garran, Australian Capital Territory, Australia
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
- Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
- Bundaberg Hospital, Bundaberg, Queensland, Australia
- Cairns Hospital, Cairns, Queensland, Australia
- Logan Hospital, Logan City, Queensland, Australia
- Mackay Base Hospital, Mackay, Queensland, Australia
- Rockhampton Hospital, Rockhampton, Queensland, Australia
- Mater Hospital, South Brisbane, Queensland, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Royal Hobart Hospital, Hobart, Tasmania, Australia
- Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Collaborators
University of Adelaide
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06120673 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.